<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591902</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200147-500</org_study_id>
    <nct_id>NCT01591902</nct_id>
  </id_info>
  <brief_title>Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®</brief_title>
  <official_title>A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theratechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theratechnologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of
      Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and
      Type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, EGRIFTA® has not been studied for longer than 1 year in human subjects, nor has
      EGRIFTA® been studied in Type 2 diabetic HIV-infected subjects who are receiving oral
      hypoglycemic agents, GLP-1 analogues, or insulin. The present study will assess the potential
      of EGRIFTA® to induce or exacerbate DR in HIV-infected subjects on antiretroviral therapy who
      have concomitant abdominal lipohypertrophy and T2DM, and explore the long-term effects of
      EGRIFTA® on glycemic control and major adverse cardiovascular event (MACE) in this
      population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale.</measure>
    <time_frame>3 years</time_frame>
    <description>Subjects will undergo an opthamologic examination including fundus photographs at 3 month intervals for duration of 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c by intensification of concomitant diabetic treatment</measure>
    <time_frame>3 years</time_frame>
    <description>HbA1c values will be obtained at screening at month 3, 6, 12, 18, 24, 30 and 36</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">648</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>EGRIFTA Treatment Grop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile, lyophilized, nonpyrogenic powder containing tesamorelin acetate with mannitol as excipient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-controlled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesamorelin</intervention_name>
    <description>Daily 2 mg subcutaneous injections of tesamorelin</description>
    <arm_group_label>EGRIFTA Treatment Grop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Control</intervention_name>
    <description>3.0 mL vials</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Subject has given written informed consent and is willing to comply with the
             requirements of the protocol;

          2. Subject is an adult man or woman (≥ 18 years old);

          3. Subject has laboratory confirmed HIV infection;

          4. Subject is receiving ART that has been stable for at least 8 weeks prior to screening;

          5. Subject has physical evidence of abdominal lipohypertrophy, as determined by the
             examining study physician;

          6. Subject has T2DM as determined by previous HbA1c ≥ 6.5%, previous fasting plasma
             glucose

               -  ≥ 126 mg/dL (7.0 mmol/L), and/or previous 2-hour plasma glucose ≥ 200 mg/dL (11.1
                  mmol/L) during oral glucose tolerance testing (OGTT), and/or previous random
                  plasma glucose ≥ 200 mg/dL (11.1 mmol/L) with symptoms of uncontrolled DM;

               -  if subject has been diagnosed with T2DM and is on glucose lowering medications
                  for greater than 1 year the above glucose parameters do not apply;

          7. Subject, at the time of screening, has HbA1c between 6.0% and 12.0%;

          8. Subject's diabetes has been treated for at least 1 year by diet alone, individuals who
             are on a stable dose (at least 3 months) of insulin, an OHA, or a GLP-1 analogue plus
             insulin to control diabetes are permitted if their HbA1C is below 6.0%. OHA, GLP-1
             analogue, or OHA/GLP-1 analogue plus insulin according to current American Diabetes
             Association (ADA) guidelines, and doses have been stable for at least 3 months;

          9. If the subject is using lipid lowering drugs, the dose must be stable for at least 2
             months prior to screening;

         10. Subject must have an electrocardiogram (ECG) without clinically significant
             abnormalities within 6 months prior to screening;

         11. Pre-menopausal women of childbearing potential are eligible only if they are not
             pregnant (negative urine pregnancy tests at screening and baseline) or lactating and
             are using an acceptable form of birth control prior to study entry and for at least 2
             months after completing treatment. Acceptable contraception is defined as two barrier
             methods, or one barrier method with a spermicide, or an intrauterine device, or an
             oral contraceptive;

         12. Women of non-childbearing potential must be post-menopausal (no menses for more than 1
             year) or surgically sterile (tubal ligation or hysterectomy);

         13. Women over 40 years old must have a negative mammogram within 6 months prior to
             screening or a mammogram will be taken at screening;

         14. Men must have a normal prostate exam and a prostate specific antigen (PSA) Individuals
             who are on a stable dose (at least 3 months) of insulin, less than or equal to 5 ng/mL
             within 6 months prior to screening or PSA and, for men 50 years of age or older, a
             prostate specific antigen will be measured at screening

        Exclusion Criteria:

          1. Subject has Type 1 DM;

          2. Subject has body mass index (BMI) &lt; 18.5 kg.m2;

          3. Subject has or has had an opportunistic infection or acquired immune deficiency
             syndrome (AIDS)-defining illness within 3 months of screening;

          4. Subject has or has had a malignancy or, for women, personal or family (first degree
             relative) history of breast cancer. Exceptions are basal cell carcinoma, in situ
             carcinoma of the cervix, in situ anal carcinoma, treated and stable cutaneous squamous
             cell carcinoma. and stable Kaposi's sarcoma;

          5. Pre-existing PDR or severe non-PDR (NPDR), defined as an ETDRS level of ≥ 53 in either
             eye;

          6. Subject has or has had cytomegalovirus (CMV) retinitis, toxoplasmosis, or any other
             ocular infection that would prevent evaluation of DR;

          7. Subject has previously been treated for DR (treatments such as laser photocoagulation,
             intravitreal injection, or vitrectomy);

          8. Subject has any of the following illnesses or conditions:

               1. hypopituitarism, history of pituitary tumor or pituitary surgery;

               2. untreated hypothyroidism;

               3. head irradiation or head trauma that has affected the somatotropic axis;

               4. uncontrolled hypertension, defined as systolic pressure &gt; 140 mm Hg and diastolic
                  pressure &gt; 90 mm Hg;

               5. unstable CV condition, defined as:

             i. acute MI; ii. unstable angina; iii. decompensated congestive heart failure (CHF,
             new onset or exacerbation); iv. stroke; v. history of any of the above within 6 months
             prior to screening; f. hepatic abnormality, defined as aspartate aminotransferase
             (AST) or alanine aminotransferase (ALT) &gt; 3 times the upper limit of normal (3 x ULN);
             g. renal abnormality, defined as serum creatinine &gt; 2 x ULN; h. lipid metabolism
             abnormality, defined as fasting triglycerides &gt; 1500 mg/dL; i. anemia, defined as
             hemoglobin ≤ 7 g/dL;

          9. Drug or hormone use as follows

               1. Men: change in regimen or supraphysiological dose of testosterone within 2 months
                  prior to screening;

               2. anabolic steroids, GH, GH secretagogue, GHRF products or analogs (including
                  EGRIFTA®), IGF-1, or IGF binding protein 3 (IGFBP 3) within 6 months prior to
                  screening;

         10. Drug or alcohol dependence within 6 months prior to screening;

         11. Subject is using or has used anorectics, anorexigenics, or anti-obesity agents within
             3 months prior to screening;

         12. Subject is pregnant or nursing;

         13. Other significant disease that, in the Investigator's opinion, would exclude the
             subject from the trial;

         14. Participation, within 30 days prior to screening, in another clinical trial of an
             investigational agent that could affect IGF-1 levels;

         15. Known hypersensitivity to the study drug treatments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Mamputu, PhD</last_name>
    <affiliation>Theratechnologies Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theratechnologies Medical Information</last_name>
    <phone>514-336-7800</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Southwest Center for HIV/AIDS</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Nelson</last_name>
      <phone>602-595-8169</phone>
    </contact>
    <investigator>
      <last_name>Timothy Kuberski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Medical Group</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilda De La Garza</last_name>
      <phone>602-604-9500</phone>
    </contact>
    <investigator>
      <last_name>Thanes Vanig, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>5P21 Rand Schrader Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Canchola</last_name>
      <phone>323-343-8281</phone>
    </contact>
    <investigator>
      <last_name>Michael Dube, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California CARE Clinic, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Cajahuaringa</last_name>
      <phone>310-557-9640</phone>
    </contact>
    <investigator>
      <last_name>Jordan Lake, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmtree Clinical Research, Inc.</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Hernandez</last_name>
      <phone>760-902-9615</phone>
    </contact>
    <investigator>
      <last_name>Richard Loftus, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Meixner</last_name>
      <phone>619-543-8241</phone>
    </contact>
    <investigator>
      <last_name>Daniel Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VAMC, Infectious Disease Section 111W</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Freasier</last_name>
      <phone>415-379-5518</phone>
    </contact>
    <investigator>
      <last_name>Phyllis Tien, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Medical Associates, PC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Granville</last_name>
      <phone>202-822-6311</phone>
    </contact>
    <investigator>
      <last_name>Theo Hodge, Jr., M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gary J. Richmond, M.D., PA</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vernon Appleby</last_name>
      <phone>954-524-2250</phone>
      <phone_ext>211</phone_ext>
    </contact>
    <investigator>
      <last_name>Gary J. Richmond, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orange County Health Department</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willie Carter</last_name>
      <phone>407-858-1436</phone>
    </contact>
    <investigator>
      <last_name>Ewa Szczypinska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenn Kuretski</last_name>
      <phone>561-832-6770</phone>
    </contact>
    <investigator>
      <last_name>Olayemi Osiyemi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rowan Tree Medical , P.A.</name>
      <address>
        <city>Wilton Manors</city>
        <state>Florida</state>
        <zip>33305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avery Woodard</last_name>
      <phone>954-533-5382</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Bartczak, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center, P.C.</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072-3436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Khan</last_name>
      <phone>248-544-9300</phone>
    </contact>
    <investigator>
      <last_name>Paul Benson, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton Clinical Research, Inc d.b.a. Central West Clinical Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Allami</last_name>
      <phone>314-652-0100</phone>
      <phone_ext>829</phone_ext>
    </contact>
    <investigator>
      <last_name>David Parks, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton Healthcare, Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Swiercz</last_name>
      <phone>314-647-2200</phone>
      <phone_ext>103</phone_ext>
    </contact>
    <investigator>
      <last_name>David Prelutsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Jersey Infectious Disease</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Freeman</last_name>
      <phone>609-927-6662</phone>
      <phone_ext>5</phone_ext>
    </contact>
    <investigator>
      <last_name>Christopher Lucasti, D.O., FACOI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harold Hamm Diabetes Center at the University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Salazar</last_name>
      <phone>405-271-4655</phone>
    </contact>
    <investigator>
      <last_name>James Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fanno Creek Clinic, LLC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Zeigler</last_name>
      <phone>503-452-0915</phone>
      <phone_ext>130</phone_ext>
    </contact>
    <investigator>
      <last_name>Gregg Coodley, M.D., FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronnie Milam</last_name>
      <phone>512-480-9660</phone>
    </contact>
    <investigator>
      <last_name>Cynthis Brinson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Hope Foundation, Inc.</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saima Azeem</last_name>
      <phone>713-844-8035</phone>
    </contact>
    <investigator>
      <last_name>James Sims, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Ghormley</last_name>
      <phone>214-857-1606</phone>
    </contact>
    <investigator>
      <last_name>Roger Bedimo, M.S., M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center, Atten: HIV Research Unit</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minerva Santos</last_name>
      <phone>214-590-2794</phone>
    </contact>
    <investigator>
      <last_name>Mamta Jain, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Access Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.J. Sarabia</last_name>
      <phone>713-526-7732</phone>
    </contact>
    <investigator>
      <last_name>Shannon R. Schrader, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Ponce</last_name>
      <phone>206-625-7373</phone>
    </contact>
    <investigator>
      <last_name>David Aboulafia, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

